Podcast
Questions and Answers
What is the primary mechanism of action of SGLT-2 inhibitors?
What is the primary mechanism of action of SGLT-2 inhibitors?
Where do SGLT-2 inhibitors primarily act to reduce glucose reabsorption?
Where do SGLT-2 inhibitors primarily act to reduce glucose reabsorption?
What is the target of SGLT-2 inhibitors in the kidneys?
What is the target of SGLT-2 inhibitors in the kidneys?
What is the effect of SGLT-2 inhibitors on filtered glucose in the kidneys?
What is the effect of SGLT-2 inhibitors on filtered glucose in the kidneys?
Signup and view all the answers
What is the overall effect of SGLT-2 inhibitors on glucose levels?
What is the overall effect of SGLT-2 inhibitors on glucose levels?
Signup and view all the answers
What is the effect of canagliflozin on glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) levels?
What is the effect of canagliflozin on glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) levels?
Signup and view all the answers
Canagliflozin is approved for the treatment of type 1 diabetes.
Canagliflozin is approved for the treatment of type 1 diabetes.
Signup and view all the answers
What is the potential benefit of canagliflozin on kidney disease?
What is the potential benefit of canagliflozin on kidney disease?
Signup and view all the answers
Canagliflozin may reduce the risk of _______________ in patients with type 2 diabetes and established cardiovascular disease.
Canagliflozin may reduce the risk of _______________ in patients with type 2 diabetes and established cardiovascular disease.
Signup and view all the answers
What is a common adverse reaction of canagliflozin?
What is a common adverse reaction of canagliflozin?
Signup and view all the answers
Canagliflozin can cause hypotension in patients with underlying kidney disease.
Canagliflozin can cause hypotension in patients with underlying kidney disease.
Signup and view all the answers
Match the following benefits of canagliflozin with their corresponding effects:
Match the following benefits of canagliflozin with their corresponding effects:
Signup and view all the answers
What is a potential risk of canagliflozin in older adults?
What is a potential risk of canagliflozin in older adults?
Signup and view all the answers
What is the recommended use of dapagliflozin in patients with type 2 diabetes?
What is the recommended use of dapagliflozin in patients with type 2 diabetes?
Signup and view all the answers
What is a common side effect of dapagliflozin?
What is a common side effect of dapagliflozin?
Signup and view all the answers
What is a serious side effect of dapagliflozin?
What is a serious side effect of dapagliflozin?
Signup and view all the answers
What is a rare but serious side effect of dapagliflozin?
What is a rare but serious side effect of dapagliflozin?
Signup and view all the answers
In which patients is dapagliflozin particularly contraindicated?
In which patients is dapagliflozin particularly contraindicated?
Signup and view all the answers
What is a potential complication of dapagliflozin in patients with a history of osteoporosis?
What is a potential complication of dapagliflozin in patients with a history of osteoporosis?
Signup and view all the answers
Dapagliflozin is indicated for the treatment of which of the following conditions?
Dapagliflozin is indicated for the treatment of which of the following conditions?
Signup and view all the answers
Which of the following is a common side effect of dapagliflozin?
Which of the following is a common side effect of dapagliflozin?
Signup and view all the answers
What is a serious side effect of dapagliflozin?
What is a serious side effect of dapagliflozin?
Signup and view all the answers
In which patients is dapagliflozin particularly contraindicated?
In which patients is dapagliflozin particularly contraindicated?
Signup and view all the answers
What is a potential complication of dapagliflozin in patients with a history of osteoporosis?
What is a potential complication of dapagliflozin in patients with a history of osteoporosis?
Signup and view all the answers
In the EMPA-REG OUTCOME trial, what was the reduction in the risk of incident or worsening nephropathy with empagliflozin compared to placebo?
In the EMPA-REG OUTCOME trial, what was the reduction in the risk of incident or worsening nephropathy with empagliflozin compared to placebo?
Signup and view all the answers
In the EMPEROR-Reduced trial, what was the reduction in the risk of cardiovascular death or heart failure hospitalization with empagliflozin compared to placebo?
In the EMPEROR-Reduced trial, what was the reduction in the risk of cardiovascular death or heart failure hospitalization with empagliflozin compared to placebo?
Signup and view all the answers
What was the reduction in the risk of major adverse cardiovascular events (MACE) with empagliflozin in the EMPA-REG OUTCOME trial?
What was the reduction in the risk of major adverse cardiovascular events (MACE) with empagliflozin in the EMPA-REG OUTCOME trial?
Signup and view all the answers
What was the reduction in the risk of cardiovascular death with empagliflozin in the EMPA-REG OUTCOME trial?
What was the reduction in the risk of cardiovascular death with empagliflozin in the EMPA-REG OUTCOME trial?
Signup and view all the answers
What was the reduction in the risk of hospitalization for heart failure with empagliflozin in the EMPA-REG OUTCOME trial?
What was the reduction in the risk of hospitalization for heart failure with empagliflozin in the EMPA-REG OUTCOME trial?
Signup and view all the answers
In the EMPEROR-Reduced trial, what was the improvement in Kansas City Cardiomyopathy Questionnaire (KCCQ) scores with empagliflozin?
In the EMPEROR-Reduced trial, what was the improvement in Kansas City Cardiomyopathy Questionnaire (KCCQ) scores with empagliflozin?
Signup and view all the answers
Study Notes
Mechanism of Action
- Canagliflozin inhibits SGLT2 in the kidneys, reducing glucose reabsorption and increasing glucose excretion in urine
- Inhibits glucose reabsorption in the proximal tubule, increasing urinary glucose excretion and reducing glucose reabsorption
- Increases GLP-1 and PYY levels, improving beta-cell function and insulin sensitivity
Type 2 Diabetes Management
- Approved for treatment of type 2 diabetes as monotherapy or with other antidiabetic agents
- Reduces HbA1c levels, fasting plasma glucose, and body weight
- Suitable for patients with inadequate glycemic control on diet and exercise, or with metformin, sulfonylureas, pioglitazone, or insulin
- Can be used in patients with established cardiovascular disease or at high risk of cardiovascular disease
Renal Effects
- Increases urinary glucose excretion, leading to osmotic diuresis and increased urine volume
- May cause acute kidney injury due to dehydration and hypovolemia, particularly in patients with pre-existing kidney disease
- Reduces albuminuria and slows progression of kidney disease in patients with diabetic nephropathy
Cardiovascular Benefits
- Reduces major adverse cardiovascular events (MACE) in patients with type 2 diabetes and established cardiovascular disease
- Reduces hospitalization for heart failure and cardiovascular death
- May reduce blood pressure and improve cardiovascular outcomes in patients with type 2 diabetes
Adverse Reactions
- Common adverse reactions include vulvovaginal candidiasis, balanitis, and urinary tract infections
- Increases risk of amputations, particularly of the toe or midfoot
- May cause hypotension, particularly in patients taking diuretics or with underlying kidney disease
- May increase risk of bone fracture, particularly in older adults
Dapagliflozin (Farxiga)
Indications
- Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
- Recommended as a first-line treatment for patients with type 2 diabetes and established cardiovascular disease or at risk of cardiovascular disease
- Can be used as a monotherapy or in combination with other antidiabetic medications, including metformin, sulfonylureas, and insulin
Side Effects
Common Side Effects
- Urinary tract infections
- Female genital mycotic infections (e.g., vaginal yeast infections)
- Increased urination
- Thirst
- Constipation
- Nausea and vomiting
Serious Side Effects
- Dehydration
- Hypotension (low blood pressure)
- Ketoacidosis (a serious metabolic complication)
- Fournier's gangrene (a rare but serious infection of the genital area)
- Increased risk of amputations (particularly in patients with a history of prior amputation)
- Bone fractures (particularly in patients with a history of osteoporosis)
Rare but Serious Side Effects
- Angioedema (a severe allergic reaction)
- Bullous pemphigoid (a serious skin condition)
- Anaphylaxis (a severe, life-threatening allergic reaction)
SGLT-2 Inhibitors
- Inhibit sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubules to reduce reabsorption of filtered glucose
Mechanism of Action
- Inhibit glucose reabsorption in the kidneys, increasing glucose excretion in urine
- Reduce glucose reabsorption in the proximal tubule, reducing glucose reabsorption and increasing urinary glucose excretion
- Increase glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) levels, improving beta-cell function and insulin sensitivity
Type 2 Diabetes Management
- Approved for treatment of type 2 diabetes as monotherapy or in combination with other antidiabetic agents
- Reduce HbA1c levels, fasting plasma glucose, and body weight
- Can be used in patients with inadequate glycemic control on diet and exercise, or with metformin, sulfonylureas, pioglitazone, or insulin
- May be used in patients with established cardiovascular disease or at high risk of cardiovascular disease
Renal Effects
- Increase urinary glucose excretion, leading to osmotic diuresis and increased urine volume
- May cause acute kidney injury due to dehydration and hypovolemia, particularly in patients with pre-existing kidney disease
- Can reduce albuminuria and slow progression of kidney disease in patients with diabetic nephropathy
Cardiovascular Benefits
- Reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes and established cardiovascular disease or at high risk of cardiovascular disease
- Reduce hospitalization for heart failure and cardiovascular death
- May reduce blood pressure and improve cardiovascular outcomes in patients with type 2 diabetes
Adverse Reactions
- Common adverse reactions: vulvovaginal candidiasis, balanitis, and urinary tract infections
- Increase risk of amputations, particularly of the toe or midfoot
- May cause hypotension, particularly in patients taking diuretics or with underlying kidney disease
- May increase risk of bone fracture, particularly in older adults
Dapagliflozin (Farxiga)
- Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
- Recommended as a first-line treatment for patients with type 2 diabetes and established cardiovascular disease or at risk of cardiovascular disease
- Can be used as a monotherapy or in combination with other antidiabetic medications, including metformin, sulfonylureas, and insulin
Side Effects of Dapagliflozin
- Common side effects: urinary tract infections, female genital mycotic infections, increased urination, thirst, constipation, nausea, and vomiting
- Serious side effects: dehydration, hypotension, ketoacidosis, Fournier's gangrene, increased risk of amputations, bone fractures
- Rare but serious side effects: angioedema, bullous pemphigoid, anaphylaxis
Empagliflozin and Type 2 Diabetes
Diabetic Nephropathy
- Slows kidney disease progression in patients with type 2 diabetes.
- Reduces the risk of incident or worsening nephropathy by 39% compared to placebo.
- Reduces the risk of progression to macroalbuminuria by 38%.
Heart Failure With Reduced Ejection Fraction
- Reduces the risk of heart failure hospitalization in patients with type 2 diabetes.
- Reduces the risk of cardiovascular death or heart failure hospitalization by 25% compared to placebo.
- Improves Kansas City Cardiomyopathy Questionnaire (KCCQ) scores, indicating improved health status and quality of life.
Cardiovascular Outcomes
- Reduces the risk of major adverse cardiovascular events (MACE) by 14% compared to placebo.
- Reduces the risk of cardiovascular death by 38%.
- Reduces the risk of hospitalization for heart failure by 35%.
- Reduces the risk of cardiovascular events in patients with established cardiovascular disease or multiple cardiovascular risk factors.
Studying That Suits You
Use AI to generate personalized quizzes and flashcards to suit your learning preferences.
Description
This quiz covers the mechanism of SGLT-2 inhibitors, which reduce glucose reabsorption in the kidneys, and their role in diabetes treatment. Learn about their effects on glucose levels and kidney function.
